Hepatitis C virus infection in hemodialysis;Infection par le virus de l'hépatite C en hémodialyse

Nephrologie

Volumn 24, Issue 3, 2003, Pages 133-141

  Kamar, N ^a   Izopet, J ^b   Rostaing, Lionel ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

Acute hepatitis C infection; Chronic hemodialysis patients; Hepatitis C virus; Interferon ; Nosocomial transmission

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFUSION; DEMENTIA; DIALYSIS; DIARRHEA; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; EPILEPSY; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOENCEPHALOPATHY; LEUKOPENIA; MALAISE; MYALGIA; NEUROLOGIC DISEASE; THROMBOCYTOPENIA; VIRUS HEPATITIS; VIRUS TRANSMISSION; VISUAL DISORDER;

ANTIVIRAL AGENTS; CROSS INFECTION; FRANCE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 0038247751     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
3. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-500.
4. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 1322-6.
5. Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46: 504-11.
6. Roth D. Hepatitis C virus: The nephrologist's view. Am J Kidney Dis 1995; 25: 3-16.
7. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-99.
8. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53.
9. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-81.
10. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-34.
11. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-74.
12. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608-14.
13. Natov SN, Lau JY, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998; 31: 920-7.
14. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: A multicenter study. J Med Virol 2000; 61: 44-51.
15. Natov SN, Pereira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial 2000; 13: 393-8.
16. Chan TM, Lok AS, Cheng IK. Hepatitis C infection among dialysis patients: A comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 944-7.
17. Dussol B, Berthezene P, Brunet P, Roubicek C, Berland Y. Hepatitis C virus infection among chronic dialysis patients in the south of France: A collaborative study. Am J Kidney Dis 1995; 25: 399-404.
18. Bruguera M, Vidal L, Sanchez-Tapias JM, Costa J, Revert L, Rodes J. Incidence and features of liver disease in patients on chronic hemodialysis. J Clin Gastroenterol 1990; 12: 298-302.
19. Bruguera M, Sanchez Tapias JM. Epidemiology of hepatitis C virus infection. Nephrol Dial Transplant 2000; 15: 2-4.
20. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
21. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, Casalino C, Ippolito G. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-10.
22. Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthelot P, Brechot C. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: Significance and therapeutic implications. Kidney Int 1993; 44: 1097-100.
23. Olmer M, Bouchouareb D, Zandotti C, de Micco P, de Lamballerie X. Transmission of the hepatitis C virus in an hemodialysis unit: Evidence for nosocomial infection. Clin Nephrol 1997; 47: 263-70.
24. Courouce AM, Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Naret C, Poignet JL. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant 1995; 10: 234-9.
25. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, Sanna R, van Der Heijden TG, van Den Hoven H, van Hamersvelt HW, Quint W, van Doorn LJ. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: A nationwide prospective study. J Infect Dis 2000; 182: 1291-9.
26. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-22.
27. Puttinger H, Vychytil A. Hepatitis B and C in peritoneal dialysis patients. Semin Nephrol 2002; 22: 351-60.
28. Okuda K, Hayashi H, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by haemodialysis. Lancet 1996; 347: 909-10.
29. Noiri E, Nakao A, Oya A, Fujita T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37: 38-42.
30. Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M, Ranghino A, Silini E, Soccio G, Dal Canton A. Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Kidney Int 1999; 56: 2286-91.
31. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29: 676-9.
32. Manzini P, Amore A, Brunetto MR, Martina G, Verme G, Bonino F, Coppo R. Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? Nephron 1996; 72: 102-3.
33. Sampietro M, Graziani G, Badalamenti S, Salvadori S, Caldarelli R, Como G, Fiorelli G. Detection of hepatitis C virus in dialysate and in blood ultrafiltrate of HCV-positive patients. Nephron 1994; 68: 140.
34. Hubmann R, Zazgornik J, Gabriel C, Garbeis B, Blauhut B. Hepatitis C virus-does it penetrate the haemodialysis membrane? PCR analysis of haemodialysis ultrafiltrate and whole blood. Nephrol Dial Transplant 1995; 10: 541-2.
35. Caramelo C, Navas S, Alberola ML, Bermejillo T, Reyero A, Carreno V. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66: 470-3.
36. Lombardi M, Cerrai T, Dattolo P, Pizzarelli F, Michelassi S, Maggiore Q, Zignego AL. Is the dialysis membrane a safe barrier against HCV infection? Nephrol Dial Transplant 1995; 10: 578-9.
37. Valtuille R, Fernandez JL, Berridi J, Moretto H, del Pino N, Rendo P, Lef L. Evidence of hepatitis C virus passage across dialysis membrane. Nephron 1998; 80: 194-6.
38. Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999; 58: 39-44.
39. Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: Molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994; 43: 415-9.
40. Sampietro M, Badalamenti S, Salvadori S, Corbetta N, Graziani G, Como G, Fiorelli G, Ponticelli C. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: Evidence for nosocomial transmission of HCV. Kidney Int 1995; 47: 911-7.
41. Stuyver L, Claeys H, Wyseur A, Van Arnhem W, De Beenhouwer H, Uytendaele S, Beckers J, Matthijs D, Leroux-Roels G, Maertens G, De Paepe M. Hepatitis C virus in a hemodialysis unit: Molecular evidence for nosocomial transmission. Kidney Int 1996; 49: 889-95.
42. de Lamballerie X, Olmer M, Bouchouareb D, Zandotti C, De Micco P. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996; 49: 296-302.
43. Katsoulidou A, Paraskevis D, Kalapothaki V, Arvanitis D, Karayiannis P, Hadjiconstantiou V, Hatzakis A. Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Nephrol Dial Transplant 1999; 14: 1188-94.
44. Hosokawa N, Esumi M, Iwasaki Y, Yanai M, Enomoto A, Kawano K. Phylogenetic evidence, by multiple clone analysis of hypervariable region 1, for the transmission of hepatitis C virus to chronic haemodialysis patients. J Viral Hepat 2000; 7: 276-82.
45. Grethe S, Gemsa F, Monazahian M, Bohme I, Uy A, Thomssen R. Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: Direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis. J Med Virol 2000; 60: 152-8.
46. Halfon P, Roubicek C, Gerolami V, Quentin Y, Khiri H, Pepe G, Berland Y. Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol 2002; 40: 1541-5.
47. Alfurayh O, Sabeel A, Al Ahdal MN, Almeshari K, Kessie G, Hamid M, Dela Cruz DM. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000; 20: 103-6.
48. Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001; 55: 477-81.
49. Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, Otero T, Moya A, Esteban R, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555-60.
50. Ross RS, Viazov S, Roggendorf M. Phylogenetic analysis indicates transmission of hepatitis C virus from an infected orthopedic surgeon to a patient. J Med Virol 2002; 66: 461-7.
51. Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, Courouce AM, Astagneau P, Buisson C, Desenclos JC. Outbreak of hepatitis C virus infection in a hemodialysis unit: Potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002; 23: 328-34.
52. Hardy NM, Chiao J, Arora N, Mars R, Jenkins SG. Hepatitis C virus in the hemodialysis setting: Detecting viral RNA from blood port caps by reverse transcription-polymerase chain reaction. Clin Nephrol 2000; 54: 143-6.
53. Blumberg A, Zehnder C, Burckhardt JJ. Prevention of hepatitis C infection in haemodialysis units. A prospective study. Nephrol Dial Transplant 1995; 10: 230-3.
54. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58: 143-50.
55. Fabrizi F, Locatelli F. Hepatitis C virus in the haemodialysis units: Novel insights by new techniques? Nephrol Dial Transplant 1999; 14: 1072-5.
56. Saab S, Brezina M, Gitnick G, Martin P, Yee HF, Jr. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001; 38: 91-7.
57. Castellano G. The natural history of hepatitis C virus infection. Nephrol Dial Transplant 2000; 15: 19-23.
58. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-65.
59. Fabrizi F, Lunghi G, Andrulli S, Pagliari B, Mangano S, Faranna P, Pagano A, Locatelli F. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997; 12: 1394-8.
60. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Soriano S, Aljama P. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000; 54: 151-6.
61. Glicklich D, Kapoian T. Should the hepatitis C positive end-stage renal disease patients be transplanted? Sem Dial 1996; 9: 5-8.
62. Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, Schmid P, Gerosa S, Gitnick G. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol 1999; 19: 383-8.
63. DuBois DB, Gretch D, dela Rosa C, Lee W, Fine J, Blagg CR, Corey L. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: Gender-related differences in viral load. Am J Kidney Dis 1994; 24: 795-801.
64. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-60.
65. Dussol B, Chicheportiche C, Cantaloube JF, Roubicek C, Biagini P, Berthezene P, Berland Y. Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients. Am J Kidney Dis 1993; 22: 574-80.
66. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, Mousa M, Gitnick G. Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey. Nephron 1998; 80: 428-33.
67. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, Payan C, Pawlotsky JM, Defer C, Bogard M, Gerolami V, Halfon P, Buisson Y, Fouqueray B, Loiseau P, Lamoril J, Lefrere JJ, Marcellin P. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 435-43.
68. Pol S, Thiers V, Nousbaum JB, Legendre C, Berthelot P, Kreis H, Brechot C. The changing relative prevalence of hepatitis C virus genotypes: Evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-3.
69. Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C - positive dialysis patients and renal transplant recipients. Am J Gastroenterol 1999; 94: 159-63.
70. Rostaing L, Borde JS, Hasle C, Bories P, Allal A, Abbal M, Durand D. Lack of effect of chronic hepatitis C virus infection on T-cell cytokine production in chronic hemodialysis patients. Am J Nephrol 2001; 21: 194-9.
71. Martin J, de Sequera P, Quiroga JA, Rico M, Fernandez M, Arocena C, Caramelo C, Carreno V. Role of haemodialysis and hepatitis C virus infection in spontaneous and induced cytokine production of patients with chronic renal disease. Cytokine 2000; 12: 1248-52.
72. Bergamini A, Bolacchi F, Cerasari G, Carvelli C, Faggioli E, Cepparulo M, Demin F, Uccella I, Bongiovanni B, Niutta P, Capozzi M, Lupi M, Piscitelli E, Rocchi G, Angelico M. Lack of evidence for the Th2 predominance in patients with chronic hepatitis C. Clin Exp Immunol 2001; 123: 451-8.
73. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-7.
74. Pol S, Zylberberg H, Fontaine H, Brechot C. Treatment of chronic hepatitis C in special groups. J Hepatol 1999; 31: 205-9.
75. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll HK, Gruenewald K. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-9.
76. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8.
77. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G, et al. Interferon-alpha-2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1834-7.
78. Casanovas Taltavull C, Baliellas C, Sese E, Iborra MJ, Benasco E, Andrès E, Gonzalez MT, Gil-Vernet S, Casais LA. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995; 27: 2229-30.
79. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414-9.
80. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-9.
81. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34: 55-60.
82. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.
83. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 220-6.
84. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120-6.
85. Kamar N, Kany M, Bories P, Ribes D, Izopet J, Durand D, Rostaing L. Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis 2001; 37: E29.
86. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
87. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-92.
88. Renders L, Weber P, Hauser I, Goerig M, Nonnast-Daniel B. Ribavirin/interferon combination therapy in hemodialysis patients. A new therapeutical option? Nephrol Dial Transplant 2002; 17: 45.
89. Gursoy M, Gur G, Arsian H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-7.
90. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, Davis C, Gretch DR. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46: 1255-63.
91. Roth D, Zucker K, Cirocco R, Burke G, Ciancio G, Esquenazi V, Swanson SJ, 3rd, Miller J. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-9.
92. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-8.
93. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.
94. Pol S, Garrigue V, Legendre C. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 335: 522; discussion 522-3.
95. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-70.
96. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
97. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-6.
98. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-5.
99. Ribes D, Arnaud C, Modesto A, Izopet J, Durand D, Rostaing L. Detrimental effect of hepatitis C virus (HCV) infection in the long-term in cadaveric renal transplant (RT) patients. Nephrol Dial Transplant 2001; 16: A82.
100. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511-5.
101. Hestin D, Guillemin F, Castin N, Le Faou A, Champigneulles J, Kessler M. Pretransplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. Transplantation 1998; 65: 741-4.
102. Thervet E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-8.
103. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: Preliminary results and side effects. Transplant Proc 1995; 27: 948-50.
104. Hanafusa T, Ichikawa Y, Yazawa K, Kishikawa H, Fukunishi T, Kanai T, Shinji Y, Nagano S. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 1998; 30: 122-4.
105. Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, Gouya N, Nakazawa H, Hashimoto E, Fuchinoue S, Hayashi N, Toma H. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 1998; 30: 3270-2.
106. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783.
107. Kamar N, Sandres-Sauné K, Selves J, Durand D, Izopet J, Rostaing L. Y at-il une place pour la ribavirine dans le traitement des transplantés rénaux infectés par le virus de l'hépatite C? Néphrologie 2003; 24: 89-94.